MiMedx (NASDAQ: MDXG) awards 50,913 restricted shares to director

Rhea-AI Filing Summary

BIERMAN JAMES L reported acquisition or exercise transactions in this Form 4 filing.

MIMEDX GROUP, INC. director James L. Bierman received an annual restricted stock grant of 50,913 shares of common stock on June 10, 2026 at $3.64 per share. The award to this non-employee director vests upon the earlier of 12 months or the next meeting of shareholders, bringing his direct holdings to 263,684 shares. This is a compensation-related equity award, not an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BIERMAN JAMES L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	50,913	$3.64	$185K

Holdings After Transaction: Common Stock — 263,684 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock grant size: 50,913 shares Grant price per share: $3.64 per share Shares held after grant: 263,684 shares +2 more

5 metrics

Restricted stock grant size 50,913 shares Annual restricted stock grant to non-employee director

Grant price per share $3.64 per share Reported value for the June 10, 2026 grant

Shares held after grant 263,684 shares Director’s total direct holdings following the transaction

Vesting condition Earlier of 12 months or next shareholder meeting Restricted stock vesting schedule for the award

Transaction code A (grant, award, or other acquisition) Form 4 classification of the equity award

Key Terms

restricted stock, Rule 16b-3, non-employee directors, vesting

4 terms

restricted stock financial

"Represents annual restricted stock grant to non-employee directors."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Rule 16b-3 regulatory

"Grant is exempt under Rule 16b-3."

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

non-employee directors financial

"Represents annual restricted stock grant to non-employee directors."

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

vesting financial

"The award vests upon the earlier of 12 months or the next meeting of shareholders."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIERMAN JAMES L

(Last) (First) (Middle)

1775 WEST OAK COMMONS COURT

(Street)

MARIETTA GEORGIA 30062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A		50,913(1)	A	$3.64	263,684	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders.

Remarks:

	/s/ William F. Hulse as attorney in fact for James L. Bierman	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MiMedx (MDXG) report for James L. Bierman?

MiMedx reported that director James L. Bierman received an annual restricted stock grant of 50,913 common shares. This equity award is classified as a grant or other acquisition, not an open-market purchase, and is part of his compensation as a non-employee director.

At what price was James L. Bierman’s restricted stock grant at MiMedx (MDXG) recorded?

The restricted stock grant to James L. Bierman was recorded at $3.64 per share. This reflects the fair value used for reporting purposes and helps investors understand the size of the director’s equity-based compensation relative to the company’s share price.

How many MiMedx (MDXG) shares does James L. Bierman hold after this grant?

Following the restricted stock grant, James L. Bierman holds 263,684 shares of MiMedx common stock directly. This figure includes the newly granted 50,913 restricted shares and shows the director’s total reported equity stake after the compensation award.

When do James L. Bierman’s MiMedx (MDXG) restricted shares vest?

The restricted stock award vests upon the earlier of 12 months or the next meeting of shareholders. This vesting schedule aligns the non-employee director’s compensation with ongoing board service and the company’s annual shareholder governance cycle.

Is James L. Bierman’s MiMedx (MDXG) stock grant an open-market purchase or a compensation award?

The transaction is a compensation-related award, not an open-market purchase. It is reported as a grant or other acquisition of 50,913 restricted shares, exempt under Rule 16b-3, reflecting standard equity compensation for a non-employee director of MiMedx.